|
Cryoviva Lifesciences in the area of stem cell banking and advanced cell-based therapeutics, has announced the commencement of a strategic collaboration to launch umbilical cord blood and stem cell collection services, in partnership with Life Keep Philippines.
Life Keep Philippines has started construction of a new facility at the upcoming Salwalk Medicity near Metro Manila with strategic support from Cryoviva. This is part of Cryoviva’s ongoing expansion across Southeast Asia, including India, Singapore, and Thailand, and reflects its commitment to making advanced healthcare and cellular therapy services more widely available in the region.
Now Cryoviva Lifesciences offers a full range of cryopreservation services in India, Thailand, Singapore and Vietnam market. This includes collecting umbilical cord blood, cord lining, and amnion tissue, processing them, isolating stem cells, and storing them safely for a long period of time. The company also runs facilities for these services and trains professionals in the collection process, helping build expertise in growing healthcare markets.
The Philippines project is being led by respected healthcare experts, Dr. Ramon Atienza and Dr. Felicidad Calip, with support from CSD Ventures. The partnership aims to encourage knowledge exchange, skill-building, and the use of global best practices in advanced therapies.
Dr. Alok Khullar, group CEO – Healthcare for Cryoviva, Reviva & Lineage Healthcare said, “The Philippines is emerging as one of the most promising healthcare markets in Southeast Asia — with a strong focus on innovation, a growing biotech sector, and a pool of highly skilled medical professionals. Through this initiative, we aim to leverage that potential while expanding Cryoviva’s expertise in stem cell banking and advanced therapeutics. We view this as a long-term opportunity to deliver meaningful breakthroughs not only for the Philippines but also for the broader Southeast Asian region and key markets like India.”
With this move, Cryoviva Lifesciences reinforces its commitment to providing high-quality, future-ready healthcare solutions through partnerships that support access, innovation, and clinical excellence across Asia, he added.
The company’s communication note also stated, “Cryoviva Lifesciences’s international growth is anchored in strategic alliances, robust institutional backing, and the integration of semi-automated processing technologies. Over the past decade, the company has scaled its operations to serve clients across 20+ countries, supported by a strong governance framework and a performance-led culture shaped by the RJ Corp group.”
|